KoBioLabs Sees IPO Building Its Credentials As Global Microbiome Player
Executive Summary
The Korean microbiome therapeutics developer KoBioLabs will launch a domestic IPO later this month and hopes to grow into a top three global company in the sector by 2025, helped by licensing deals.